HSBC Maintains Buy on BioNTech, Raises Price Target to $136
Portfolio Pulse from Benzinga Newsdesk
HSBC analyst Yifeng Liu has maintained a Buy rating on BioNTech (NASDAQ:BNTX) and raised the price target from $97 to $136.
October 07, 2024 | 5:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HSBC analyst Yifeng Liu has maintained a Buy rating on BioNTech and increased the price target from $97 to $136, indicating a positive outlook.
The increase in price target from $97 to $136 by HSBC suggests a strong positive outlook for BioNTech, likely boosting investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100